Exact Sciences Corp
NASDAQ:EXAS

  • LAST PRICE
    59.4800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    50.0000/ 6
  • Ask / Lots
    50.5000/ 4
  • Open / Previous Close
    0.0000 / 59.4800
  • Day Range
    ---
  • 52 Week Range
    56.0500
    100.7700
  • Volume
    34,384

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 14 hours ago by MT Newswires
      Companies Mentioned: EXAS
      04:58 PM EDT, 05/08/2024 (MT Newswires) -- Exact Sciences (EXAS) shares were plummeting 12% in after-hours activity Wednesday after reporting wider Q1 net loss. The company's net loss was $0.60 per diluted share, wider than a loss of $0.42 a year ea...

    • 14 hours ago by MT Newswires
      Companies Mentioned: EXAS
      04:25 PM EDT, 05/08/2024 (MT Newswires) -- ...

    • 15 hours ago by Business Wire
      Companies Mentioned: EXAS

      Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million for the first quarter ended March 31, 2024, compared to $602 million for the same period of 2023.

    • 15 hours ago by Dow Jones
      Companies Mentioned: EXAS
      accrual of $18.9 million in the first quarter of 2023 based on the Company's best estimate of the probable loss on this matter. (8) The Company took proactive measures to address the impact of inflation and market volatility, and also simplify the organizational structure and prioritize programs that will have the greatest impact on improving cancer care. This resulted in a reduction of the Company's international workforce in the first quarter of 2023. The adjustment to EBITDA represents personnel expenses incurred as a result of these proactive measures, a majority of which includes severance and accelerated stock-based compensation. EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended March 31, ------------------------------------ 2024 2023 --------------------------------- ------------ ---------- Net cash used in operating activities $ (82,311) $ (38,215) Net cash provided by (used in) investing activities (171,438) 82,941 Net cash provided by (used in) financing activities (3,002) 133,596 Effects of exchange rate changes on cash and cash equivalents (1,140) 550 ------------ ---------- Net increase (decrease) in cash, cash equivalents and restricted cash (257,891) 178,872 Cash, cash equivalents and restricted cash, beginning of period 609,675 242,790 ------------ ---------- Cash, cash equivalents and restricted cash, end of period $ 351,784 $ 421,662 ============ ========== Reconciliation of free cash flow: Net cash used in operating activities $ (82,311) $ (38,215) Purchases of property, plant and equipment (37,649) (29,360) ------------ ---------- Free cash flow $ (119,960) $ (67,575) ============ ==========

    • 15 hours ago by Dow Jones
      Companies Mentioned: EXAS
      accrual of $18.9 million in the first quarter of 2023 based on the Company's best estimate of the probable loss on this matter. (8) The Company took proactive measures to address the impact of inflation and market volatility, and also simplify the organizational structure and prioritize programs that will have the greatest impact on improving cancer care. This resulted in a reduction of the Company's international workforce in the first quarter of 2023. The adjustment to EBITDA represents personnel expenses incurred as a result of these proactive measures, a majority of which includes severance and accelerated stock-based compensation. EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended March 31, ------------------------------------ 2024 2023 --------------------------------- ------------ ---------- Net cash used in operating activities $ (82,311) $ (38,215) Net cash provided by (used in) investing activities (171,438) 82,941 Net cash provided by (used in) financing activities (3,002) 133,596 Effects of exchange rate changes on cash and cash equivalents (1,140) 550 ------------ ---------- Net increase (decrease) in cash, cash equivalents and restricted cash (257,891) 178,872 Cash, cash equivalents and restricted cash, beginning of period 609,675 242,790 ------------ ---------- Cash, cash equivalents and restricted cash, end of period $ 351,784 $ 421,662 ============ ========== Reconciliation of free cash flow: Net cash used in operating activities $ (82,311) $ (38,215) Purchases of property, plant and equipment (37,649) (29,360) ------------ ---------- Free cash flow $ (119,960) $ (67,575) ============ ==========

Peers Headlines